Proposals for leflunomide use to avoid lung injury in patients with rheumatoid arthritis

Shigeko Inokuma, Takeo Sato, Akira Sagawa, Takemasa Matsuda, Tamiko Takemura, Takeshi Ohtsuka, Yukihiko Saeki, Tsutomu Takeuchi, Tetsuji Sawada

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Among the 5,043 consecutive patients registered in the postmarketing surveillance for leflunomide, 61 were reported to have lung injury and 24 died from it. The adjusted multivariate logistic regression analysis of the risk factors showed that preexisting interstitial lung disease posed the greatest risk, as well as loading dose, smoking history, and low body weight of 40 kg or less with odds ratios of 8.17, 3.97, 3.12, and 2.91, respectively. In 12 patients, lung injury developed even 2 months after leflunomide withdrawal. When patients with (n = 9) and without (n = 13) fatal outcome were compared, eight out of the former, and six out of the latter had preexisting interstitial lung disease; the former showed severe hypoxemia, high serum C-reactive protein level, hypoalbuminemia, and continuous lymphocytopenia, and required mechanical ventilation. On the basis of these results and literature review, the committee proposes that leflunomide should only be recommended as a second-line drug, should not be administered to patients with preexisting interstitial lung disease, should also not be administered to patients with smoking history or those with low body weight, and should be administered without loading dose. Careful monitoring is necessary, and when lung injury develops, leflunomide elimination using colestyramine is mandatory.

Original languageEnglish
Pages (from-to)442-446
Number of pages5
JournalModern Rheumatology
Volume18
Issue number5
DOIs
Publication statusPublished - 2008
Externally publishedYes

Fingerprint

leflunomide
Lung Injury
Rheumatoid Arthritis
Interstitial Lung Diseases
Smoking
History
Body Weight
Cholestyramine Resin
Hypoalbuminemia
Lymphopenia
Fatal Outcome
Advisory Committees
Artificial Respiration
C-Reactive Protein
Blood Proteins
Logistic Models
Odds Ratio
Regression Analysis

Keywords

  • Leflunomide
  • Lung injury
  • Proposals for leflunomide use
  • Rheumatoid arthritis

ASJC Scopus subject areas

  • Rheumatology

Cite this

Inokuma, S., Sato, T., Sagawa, A., Matsuda, T., Takemura, T., Ohtsuka, T., ... Sawada, T. (2008). Proposals for leflunomide use to avoid lung injury in patients with rheumatoid arthritis. Modern Rheumatology, 18(5), 442-446. https://doi.org/10.1007/s10165-008-0088-2

Proposals for leflunomide use to avoid lung injury in patients with rheumatoid arthritis. / Inokuma, Shigeko; Sato, Takeo; Sagawa, Akira; Matsuda, Takemasa; Takemura, Tamiko; Ohtsuka, Takeshi; Saeki, Yukihiko; Takeuchi, Tsutomu; Sawada, Tetsuji.

In: Modern Rheumatology, Vol. 18, No. 5, 2008, p. 442-446.

Research output: Contribution to journalArticle

Inokuma, S, Sato, T, Sagawa, A, Matsuda, T, Takemura, T, Ohtsuka, T, Saeki, Y, Takeuchi, T & Sawada, T 2008, 'Proposals for leflunomide use to avoid lung injury in patients with rheumatoid arthritis', Modern Rheumatology, vol. 18, no. 5, pp. 442-446. https://doi.org/10.1007/s10165-008-0088-2
Inokuma, Shigeko ; Sato, Takeo ; Sagawa, Akira ; Matsuda, Takemasa ; Takemura, Tamiko ; Ohtsuka, Takeshi ; Saeki, Yukihiko ; Takeuchi, Tsutomu ; Sawada, Tetsuji. / Proposals for leflunomide use to avoid lung injury in patients with rheumatoid arthritis. In: Modern Rheumatology. 2008 ; Vol. 18, No. 5. pp. 442-446.
@article{f257e17b554a4e9a82c77bd893275836,
title = "Proposals for leflunomide use to avoid lung injury in patients with rheumatoid arthritis",
abstract = "Among the 5,043 consecutive patients registered in the postmarketing surveillance for leflunomide, 61 were reported to have lung injury and 24 died from it. The adjusted multivariate logistic regression analysis of the risk factors showed that preexisting interstitial lung disease posed the greatest risk, as well as loading dose, smoking history, and low body weight of 40 kg or less with odds ratios of 8.17, 3.97, 3.12, and 2.91, respectively. In 12 patients, lung injury developed even 2 months after leflunomide withdrawal. When patients with (n = 9) and without (n = 13) fatal outcome were compared, eight out of the former, and six out of the latter had preexisting interstitial lung disease; the former showed severe hypoxemia, high serum C-reactive protein level, hypoalbuminemia, and continuous lymphocytopenia, and required mechanical ventilation. On the basis of these results and literature review, the committee proposes that leflunomide should only be recommended as a second-line drug, should not be administered to patients with preexisting interstitial lung disease, should also not be administered to patients with smoking history or those with low body weight, and should be administered without loading dose. Careful monitoring is necessary, and when lung injury develops, leflunomide elimination using colestyramine is mandatory.",
keywords = "Leflunomide, Lung injury, Proposals for leflunomide use, Rheumatoid arthritis",
author = "Shigeko Inokuma and Takeo Sato and Akira Sagawa and Takemasa Matsuda and Tamiko Takemura and Takeshi Ohtsuka and Yukihiko Saeki and Tsutomu Takeuchi and Tetsuji Sawada",
year = "2008",
doi = "10.1007/s10165-008-0088-2",
language = "English",
volume = "18",
pages = "442--446",
journal = "Modern Rheumatology",
issn = "1439-7595",
publisher = "Springer Japan",
number = "5",

}

TY - JOUR

T1 - Proposals for leflunomide use to avoid lung injury in patients with rheumatoid arthritis

AU - Inokuma, Shigeko

AU - Sato, Takeo

AU - Sagawa, Akira

AU - Matsuda, Takemasa

AU - Takemura, Tamiko

AU - Ohtsuka, Takeshi

AU - Saeki, Yukihiko

AU - Takeuchi, Tsutomu

AU - Sawada, Tetsuji

PY - 2008

Y1 - 2008

N2 - Among the 5,043 consecutive patients registered in the postmarketing surveillance for leflunomide, 61 were reported to have lung injury and 24 died from it. The adjusted multivariate logistic regression analysis of the risk factors showed that preexisting interstitial lung disease posed the greatest risk, as well as loading dose, smoking history, and low body weight of 40 kg or less with odds ratios of 8.17, 3.97, 3.12, and 2.91, respectively. In 12 patients, lung injury developed even 2 months after leflunomide withdrawal. When patients with (n = 9) and without (n = 13) fatal outcome were compared, eight out of the former, and six out of the latter had preexisting interstitial lung disease; the former showed severe hypoxemia, high serum C-reactive protein level, hypoalbuminemia, and continuous lymphocytopenia, and required mechanical ventilation. On the basis of these results and literature review, the committee proposes that leflunomide should only be recommended as a second-line drug, should not be administered to patients with preexisting interstitial lung disease, should also not be administered to patients with smoking history or those with low body weight, and should be administered without loading dose. Careful monitoring is necessary, and when lung injury develops, leflunomide elimination using colestyramine is mandatory.

AB - Among the 5,043 consecutive patients registered in the postmarketing surveillance for leflunomide, 61 were reported to have lung injury and 24 died from it. The adjusted multivariate logistic regression analysis of the risk factors showed that preexisting interstitial lung disease posed the greatest risk, as well as loading dose, smoking history, and low body weight of 40 kg or less with odds ratios of 8.17, 3.97, 3.12, and 2.91, respectively. In 12 patients, lung injury developed even 2 months after leflunomide withdrawal. When patients with (n = 9) and without (n = 13) fatal outcome were compared, eight out of the former, and six out of the latter had preexisting interstitial lung disease; the former showed severe hypoxemia, high serum C-reactive protein level, hypoalbuminemia, and continuous lymphocytopenia, and required mechanical ventilation. On the basis of these results and literature review, the committee proposes that leflunomide should only be recommended as a second-line drug, should not be administered to patients with preexisting interstitial lung disease, should also not be administered to patients with smoking history or those with low body weight, and should be administered without loading dose. Careful monitoring is necessary, and when lung injury develops, leflunomide elimination using colestyramine is mandatory.

KW - Leflunomide

KW - Lung injury

KW - Proposals for leflunomide use

KW - Rheumatoid arthritis

UR - http://www.scopus.com/inward/record.url?scp=53549128108&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=53549128108&partnerID=8YFLogxK

U2 - 10.1007/s10165-008-0088-2

DO - 10.1007/s10165-008-0088-2

M3 - Article

VL - 18

SP - 442

EP - 446

JO - Modern Rheumatology

JF - Modern Rheumatology

SN - 1439-7595

IS - 5

ER -